EBR Systems, Inc.
EBR Systems, Inc. develops and commercializes the WiSE CRT System, a leadless cardiac resynchronization therapy platform used to help treat heart failure patients who need pacing support. The company is transitioning from development to U.S. commercialization after FDA approval in April 2025, with its business centered on hospital adoption, reimbursement coverage, and clinical workflow integration.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaThe company's core commercial product for cardiac resynchronization therapy using leadless pacing technology.
Tuotteet
Raportoitu · osuus liikevaihdosta- Wi SECRT System95,7 %
- Battery Replacements3,3 %
- Surgical Tool Kits0,9 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
EBR sells primarily to hospitals and the physicians who implant and use the WiSE CRT System in cardiac procedures. Adoption depends on electrophysiologists, cath lab teams, and hospital administrators that evaluate clinical utility, workflow fit, and reimbursement coverage before expanding use across sites.
Hospitals that purchase and use WiSE CRT for approved cardiac procedures, driven by clinical demand and reimbursement coverage.
Physicians and clinical teams who decide whether to adopt the technology and how frequently it is used per site.
Hospitals in Australia, the United Kingdom and the European Union targeted for future launch once approvals and coverage are in place.
Strategia
EBR's near-term strategy is to scale U.S. commercialization by expanding the field team, improving hospital training, and increasing implants per site. The company is also pursuing reimbursement coverage and preparing for international expansion, but execution depends on regulatory approvals, clinical adoption and available funding.
The company now needs to convert FDA approval into recurring hospital usage and revenue.
Coverage determines whether hospitals can economically adopt the system at scale.
OUS markets could expand the addressable market once regulatory and payment hurdles are cleared.
Maantiede
The company is currently focused on the United States, where WiSE received FDA approval in April 2025 and commercial launch began in the second quarter of 2025. Outside the U.S., EBR is preparing for future commercialization in Australia, the United Kingdom and the European Union, but those markets depend on regulatory approvals, certification and payment coverage.
Riskit
EBR remains a development-to-commercialization company with substantial going-concern risk and dependence on external financing. Its business is also exposed to regulatory, reimbursement and adoption risk because WiSE is its only FDA-approved product and success depends on hospital uptake, post-marketing compliance and continued access to capital.
- Going concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea
The company expects continued operating losses and negative cash flow, so it may need additional capital to fund commercialization.
Kohdistuu: Cash runway and ability to continue operations
- Single-product concentrationVaikutus: KorkeaTodennäköisyys: Korkea
WiSE CRT is the only FDA-approved product, so revenue generation depends on one platform succeeding commercially.
Kohdistuu - Regulatory compliance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Post-marketing FDA obligations, cGMP and reporting requirements can drive cost and create withdrawal risk if not met.
Kohdistuu: Product approval status and operating costs
- Reimbursement and market-access riskVaikutus: Korkea
Hospitals may not adopt the system broadly without adequate CMS and payer coverage.
Kohdistuu: U.S. launch economics and procedure volume
- Competitive pressureVaikutus: KeskitasoTodennäköisyys: Matala
Large, well-capitalized medtech competitors can outspend EBR on sales, evidence generation and physician engagement.
Kohdistuu: Market share and pricing
Kirjanpito
Harkinnanvaraiset erätCommercial launch in 2025 makes timing and point-in-time recognition important as product shipments begin.
Vaikutus: Affects reported revenue timing and quarterly comparability
Management disclosed substantial doubt about continuing as a going concern within twelve months.
Vaikutus: Signals financing dependence and affects investor interpretation of liquidity
Share-based awards are a meaningful non-cash expense in a pre-profit company.
Vaikutus: Inflates operating expenses and reduces comparability of adjusted metrics
Loan and security agreements create cash and non-cash interest costs.
Vaikutus: Affects net loss and leverage analysis
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
iRhythm Holdings, Inc.
IRTC · Surgical & Medical Instruments & Apparatus
Kestra Medical Technologies, Ltd
KMTS · Surgical & Medical Instruments & Apparatus
Kestra Medical Technologies is a U.S.-based commercial-stage medical device company focused on wearable cardiac monitoring and therapeutic intervention.
Corvex, Inc.
MOVE · Services-Computer Processing & Data Preparation
Edwards Lifesciences Corp
EW · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Edwards Lifesciences designs and sells structural heart therapies used to treat advanced cardiovascular disease, with a portfolio centered on transcatheter and surgical valve technologies.
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
HeartBeam, Inc.
BEAT · Surgical & Medical Instruments & Apparatus
Päivitetty: 24.9.2026